A Phase 1 Study in Patients With Hematological Malignancies to Evaluate Safety, Tolerability and Efficacy of Karonudib
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
- 试验地点
- 7
- 主要终点
- Safety of Karonudib (TH1579)
研究概览
简要总结
The primary objective of this study is to determine safety and tolerability of Karonudib for the treatment of hematological malignancies.
Secondary objectives are to determine a recommended RP2D and schedule for further development of Karonudib, to determine the pharmacokinetics of Karonudib, to look for evidence of treatment efficacy. Overall survival will also be recorded.
详细描述
Primary Objective Part I
- To determine the safety and tolerability of Karonudib in escalating doses for the treatment of patients with advanced relapsed/refractory Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) , Diffuse Large B-Cell Lymphoma, Multiple Myeloma (MM) and high-risk Myelodysplastic Syndrome (MDS)AML, ALL, DLBCL, Burkitt´s lymphoma, multiple myeloma and high-risk MDS Primary Objective Part II
- To determine the safety and tolerability of Karonudib in combination with standard of care treatment, Idarubicinother anti-cancer agents for the treatment of patients with advanced progressive, relapsed/refractory AML, and high-risk MDS
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent.
- •Age 18-75 years (may be extended to older if deemed fit).
- •The patient has received standard of care treatments and has refractory or relapsed or progressive disease with no suitable standard of care options available.
- •For expansion cohort (Cohort V): Patients can only have received a maximum of 70% of anthracycline lifetime exposure to date of proposed dosing day.
- •Cohorts I-IV: AML, ALL, DLBCL, Burkitt lymphoma, multiple myeloma or high-risk MDS, according to the WHO 2016 criteria.
- •Expansion cohort (Cohort V): Relapsed, Recurrent or Progressive AML or MDS according to the ELN 2017 criteriaWHO 2016 criteria.
- •For expansion cohort (Cohort V): Patients can only have received a maximum of 70% of anthracycline lifetime exposure to date of proposed dosing day.
- •The patient has received standard of care treatments and has refractory or relapsed disease with only experimental therapies as further treatment options.
- •Life expectancy of at least 8 weeks (as per investigators clinical assessment).
- •ECOG PFS 0-2
- •Patients must have measurable disease by blood or bone marrow or imaging examination.
- •Have a normal left ventricular ejection fraction (LVEF) based on institutional ranges.
- •Adequate hepatic and renal function defined as:
- •Total bilirubin < 3 x ULN (does not apply to patients with Gilberts Syndrome).
- •AST and ALT ≤ 5 x ULN.
- •The calculated GFR is at least 30 ml/min using Cockcroft-Gault method.
- •Platelet count≥10 x 109/L. (Can be supported by platelet transfusion)
- •Subject must be able to take oral medication.
- •Negative pregnancy test according to CTFG guidance 2014 for females of child-producing potential.
排除标准
- •Age less than 18 years.
- •Less than 4 weeks since stopping previous systemic chemotherapy treatment with the exception of stable dose Hydroxyurea, Trophosphamide, oral Cyclophosphamide, ImID or Thioguanine which needs to be stopped 10 x t1/2 prior to Karonudib administration.
- •Less than 1 week since stopping palliative radiotherapy.
- •Less than 2 weeks after surgery except access surgical procedures.
- •Less than 6 months since a clinically significant cardiovascular event such as myocardial infarction, unstable angina, angioplasty, bypass surgery, stroke or TIA.
- •Congestive heart failure NYHA class > II.
- •History of arrhythmias or arrhythmias discovered during the screening period (apart from atrial fibrillation without ventricular tachycardia and premature extra beats).
- •Patients requiring anti-arrhythmic drugs except for stable dose beta-blocking or calcium channel blocking agents.
- •QTc interval >470 ms at baseline (Fridericia correction).
- •Use of Fentanyl (must be stopped at least 1 week prior to initiation of Karonudib).
- •Use of anti-oxidants vitamins and Acetylcysteine (must be stopped within 48 hours of starting treatment with Karonudib).
- •Use of antidepressant medications which are substrate for CYP2D6 (must be stopped at least 3 weeks prior to starting treatment with Karonudib).
- •Any severe acute or chronic medical condition that places the patient at increased risk or interferes with the interpretation of study results.
- •Intracerebral engagement (patient with previously known engagement are eligible provided that there is no evidence of disease progression for a minimum of 8 weeks prior to inclusion.
- •Known acute or chronic infection with hepatitis B or C except for DNA-negative hepatitis B with stable dose anti-viral agents.
- •Known HIV infection.
- •Pregnant or breast-feeding women.
- •Patients with reproductive potential not implementing accepted and effective means of contraception.
- •Participation in any other clinical trial with a pharmaceutical product within 5 x t½, or minimum 1 week, since last dosing of the IMP, whichever is the shorter.
- •Acute promyelocytic leukemia (AML M3).
- •Uncontrolled ongoing systemic or localized infection.
- •Unable to comply with study procedures.
- •Peripheral neurological toxicity CTCAE grade 2 or higher.
研究组 & 干预措施
Dose escalation
Karonudib is an oral inhibitor of MTH1 and will be supplied as an oral solution to be taken every other day. There are three planned dose cohorts. Patients will be given every second day dosing.
干预措施: Karonudib (Drug)
结局指标
主要结局
Safety of Karonudib (TH1579)
时间窗: 28 days, first treatment cycle for the patient.
Grade and frequency of AE and SAE using the CTCAE version 5.0
Tolerability of Karonudib (TH1579)
时间窗: 28 days, first treatment cycle for the patient.
Grade and frequency of AE and SAE using the CTCAE version 5.0
Primary Objective Part I • To determine the safety and tolerability of Karonudib in escalating doses for the treatment of patients with advanced relapsed/refractory Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) , Diffuse Large B-Cell Lymphoma, Multiple Myeloma (MM) and high-risk Myelodysplastic Syndrome (MDS) Primary Objective Part II To determine the safety and tolerability of Karonudib in combination with other anti-cancer agents for the treatment of patients with advance
Primary Objective Part I • To determine the safety and tolerability of Karonudib in escalating doses for the treatment of patients with advanced relapsed/refractory Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) , Diffuse Large B-Cell Lymphoma, Multiple Myeloma (MM) and high-risk Myelodysplastic Syndrome (MDS) Primary Objective Part II To determine the safety and tolerability of Karonudib in combination with other anti-cancer agents for the treatment of patients with advance
次要结局
- Preliminary signs of clinical efficacy of Karonudib.(28 days, first treatment cycle for the patient.)